Abstract
Introduction: Pancreatic cancer afflicts over 33,000 people in the United States yearly and has an extremely poor prognosis. The five-year survival rate stands at less than 5%, due largely to late presentation and resistance to standard therapies. Gemcitabine is the standard of care for unresectable tumors; however only 25% of patients respond to gemcitabine and chemoresistance quickly emerges. To study mechanisms by which resistance arises in pancreatic tumors, we have isolated two gemcitabine-resistant stable cell lines from the human pancreatic cancer line, L3.6pl, a derivative of COLO 357 and AsPC-1.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
